Bristol Myers (BMY) faces a patent cliff, but a robust pipeline and CAR-T optionality plus 4.3% yield could spark upside—see ...
We don’t see it during the moment itself, but every circumstance has the potential to turn into a fond memory – all it takes is being fully present.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results